TNF-α, TNF-β, IL-6, and IL-10 Polymorphisms in Patients with Lung Cancer

Apart from cigarette smoking, genetic factors seem to be of importance in the development of lung cancer. The present case-control study investigated frequencies of five inflammatory response gene polymorphisms (TNF-α-308, TNF-β-Intron1-252, IL-6-174, IL-10-819 and IL-10-1082) in patients with lung cancer and controls. The study population consisted of 117 patients with lung cancer (77 patients with NSCLC, including 40 Squamous Cell Carcinoma and 26 Adenocarcinoma, and 40 patients with SCLC), 117 matched controls without pulmonary disease and 243 healthy individuals (population control). Genotype analyses revealed no difference in genotype frequencies using matched-pair analysis. However, in comparison to the population control, the IL-10-1082 genotypes carrying the G allele appeared with higher frequency in the SCLC group (p = 0.006) [SCLC: 84.6%, population controls: 64.6%]. This yields an odds ratio of 3.01 for SCLC (95% CI = [1.21, 7.48]). No associations were seen for all other polymorphisms analysed. The study raises the possibility of a correlation between the IL-10-1082_G allele and the presence of SCLC in a German population. The functional IL-10-1082 polymorphism correlates with altered IL-10 levels and might influence lung cancer susceptibility by altered inflammatory responses in the airways.

[1]  S. Dubinett,et al.  Non-small cell lung cancer-derived soluble mediators and prostaglandin E2 enhance peripheral blood lymphocyte IL-10 transcription and protein production. , 1996, Journal of immunology.

[2]  Dale R. Nyholt,et al.  Genetic case-control association studies – correcting for multiple testing , 2001, Human Genetics.

[3]  A. Blakemore,et al.  Single base polymorphism in the human tumour necrosis factor alpha (TNF alpha) gene detectable by NcoI restriction of PCR product. , 1992, Human molecular genetics.

[4]  P. Whorwell,et al.  Interleukin-10 (IL-10) genotypes in inflammatory bowel disease. , 1999, Tissue antigens.

[5]  A. Sher,et al.  Diversity of Cytokine Synthesis and Function of Mouse CD4+ T Cells , 1991, Immunological reviews.

[6]  M. Howard,et al.  Biological properties of interleukin 10 , 1992, Journal of Clinical Immunology.

[7]  C. Vogelmeier,et al.  TNF‐α‐, TNF‐β‐, IL‐6‐, and IL‐10‐promoter polymorphisms in patients with chronic obstructive pulmonary disease , 2005 .

[8]  R. Westendorp,et al.  Interleukin 10 secretion in relation to human IL-10 locus haplotypes. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[9]  G. Catalano,et al.  Serum interleukin-10 levels as a prognostic factor in advanced non-small cell lung cancer patients. , 2000, Chest.

[10]  K P Offord,et al.  Higher risk of lung cancer in chronic obstructive pulmonary disease. A prospective, matched, controlled study. , 1986, Annals of internal medicine.

[11]  N. Webster,et al.  Genotype and interleukin-10 responses after cardiopulmonary bypass. , 2003, British journal of anaesthesia.

[12]  J. Balibrea,et al.  Nitrite/ nitrate and cytokine levels in bronchoalvelar lavage fluid of lung cancer patients , 1994, Cancer.

[13]  A. Balsa,et al.  IL-6 promoter polymorphisms in rheumatoid arthritis , 2000, Genes and Immunity.

[14]  C G Figdor,et al.  Interleukin 10(IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes , 1991, The Journal of experimental medicine.

[15]  Jane Worthington,et al.  Genetic variation in the interleukin 10 gene promoter and systemic lupus erythematosus. , 1997, The Journal of rheumatology.

[16]  K. Chung,et al.  Balance of matrix metalloprotease-9 and tissue inhibitor of metalloprotease-1 from alveolar macrophages in cigarette smokers. Regulation by interleukin-10. , 2000, American journal of respiratory and critical care medicine.

[17]  M. Billah,et al.  IL-10 inhibits transcription of cytokine genes in human peripheral blood mononuclear cells. , 1994, Journal of immunology.

[18]  Michael Krawczak,et al.  Genetic association studies of bronchial asthma – a need for Bonferroni correction? , 2000, Human Genetics.

[19]  J. Pritchard,et al.  Use of unlinked genetic markers to detect population stratification in association studies. , 1999, American journal of human genetics.

[20]  C. Lenfant,et al.  Global Initiative for chronic obstructive lung disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease , 2006 .

[21]  P. Barnes,et al.  Haplotype associated with low interleukin-10 production in patients with severe asthma , 1998, The Lancet.

[22]  M. Lazarus,et al.  An investigation of polymorphism in the interleukin-10 gene promoter. , 1997, European journal of immunogenetics : official journal of the British Society for Histocompatibility and Immunogenetics.

[23]  Y. Nagamachi,et al.  The study of tumor necrosis factor beta gene polymorphism in lung cancer patients , 1994, Cancer.

[24]  D. Arveiler,et al.  New polymorphisms in the interleukin‐10 gene – relationships to myocardial infarction , 2001, European journal of clinical investigation.

[25]  S. Ebrahim,et al.  'Mendelian randomization': can genetic epidemiology contribute to understanding environmental determinants of disease? , 2003, International journal of epidemiology.

[26]  J S Yudkin,et al.  The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. , 1998, The Journal of clinical investigation.

[27]  Lung cancer and chronic obstructive pulmonary disease. , 1996, The Medical clinics of North America.

[28]  Miller,et al.  Experimental evidence from an animal model of adenocarcinoma that chronic inflammation enhances lung cancer risk , 2000, Chest.

[29]  H. Fujiki,et al.  A New Function of Green Tea: Prevention of Lifestyle‐related Diseases , 2001, Annals of the New York Academy of Sciences.

[30]  W. Ollier,et al.  IL-10 gene promoter polymorphisms in rheumatoid arthritis. , 1998, Scandinavian journal of rheumatology.

[31]  H. Mcdevitt,et al.  Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[32]  Muin J Khoury,et al.  Mendelian randomisation: a new spin or real progress? , 2003, The Lancet.

[33]  N Risch,et al.  The Future of Genetic Studies of Complex Human Diseases , 1996, Science.

[34]  U. Spengler,et al.  Polymorphic structure of the tumor necrosis factor (TNF) locus: an NcoI polymorphism in the first intron of the human TNF-beta gene correlates with a variant amino acid in position 26 and a reduced level of TNF- beta production , 1991, The Journal of experimental medicine.

[35]  J. Whang‐Peng,et al.  An analysis of cytokine status in the serum and effusions of patients with tuberculous and lung cancer. , 2001, Lung cancer.

[36]  R. Radcliffe,et al.  Tnfa and Il‐10 deficiencies have contrasting effects on lung tumor susceptibility: Gender‐dependent modulation of IL‐10 haploinsufficiency , 2003, Molecular carcinogenesis.

[37]  A. Malkinson,et al.  Susceptibility to neoplastic and non-neoplastic pulmonary diseases in mice: genetic similarities. , 2004, American journal of physiology. Lung cellular and molecular physiology.

[38]  J. Uliana Effects of a polymorphism in the human tumor necrosis factor a promoter on transcriptional activation (geneticsymajor histocompatibility complexycytokineygene regulationyautoimmune diseases) , 1997 .

[39]  H. Suemizu,et al.  Clinical implications of interleukin (IL)-10 induced by non-small-cell lung cancer. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[40]  H. Wichmann,et al.  Lung cancer and cigarette smoking in women: A multicenter case‐control study in Europe , 2000, International journal of cancer.

[41]  R. Locksley,et al.  Altered Immune Responses in Interleukin 10 Transgenic Mice , 1997, The Journal of experimental medicine.

[42]  R. Fimmers,et al.  Differential regulation of interleukin-10 production by genetic and environmental factors – a twin study , 2002, Genes and Immunity.

[43]  K. Wiktorowicz,et al.  [Biological properties of interleukin 10]. , 1994, Postepy higieny i medycyny doswiadczalnej.

[44]  G. Hillerdal,et al.  Increased risk for cancer following sarcoidosis. , 1999, American journal of respiratory and critical care medicine.

[45]  R. Dummer,et al.  HLA-G and IL-10 expression in human cancer--different stories with the same message. , 2003, Seminars in cancer biology.

[46]  C. Gutiérrez,et al.  Interindividual variations in constitutive interleukin-10 messenger RNA and protein levels and their association with genetic polymorphisms1 , 2003, Transplantation.

[47]  J. Bidwell,et al.  A novel NlaIII polymorphism in the human IL-6 promoter. , 1998, European journal of immunogenetics : official journal of the British Society for Histocompatibility and Immunogenetics.

[48]  C I Amos,et al.  Is there a genetic basis for lung cancer susceptibility? , 1999, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.